Gemcitabine With Curcumin for Pancreatic Cancer

Rambam Health Care Campus

Status and phase: Completed; Phase 2

Conditions: Pancreatic Cancer

Treatments: Drug: curcumin (+ gemcitabine)

Study type: Interventional

Funder types: Other

Identifiers

NCT00192842

RonCurcuminPancreas.CTIL

Details and patient eligibility

About

The study hypotheasis is that curcumin, a natural compound with a potent antiproliferative effect, can improve the efficacy of the standard chemotherapy gemcitabine in patients with advanced pancreatic cancer. That is why the patients are given a daily oral dose of 8 gr of curcumin along the chemotherapeutic protocol of weekly gemcitabine.

Enrollment: 17 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• locally advanced or metastatic adenocarcinoma of the pancreas
• no prior chemotherapy
• performance status 0-2
• adequate hematology and chemistry

Exclusion criteria

• serious concurrent medical condition

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)